Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Budipine is a low affinity, N-methyl-D-aspartate receptor antagonist,is an antiparkinsonian agent.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 59.00 | |
10 mg | In stock | $ 97.00 | |
25 mg | In stock | $ 195.00 | |
50 mg | In stock | $ 372.00 | |
100 mg | In stock | $ 549.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 65.00 |
Description | Budipine is a low affinity, N-methyl-D-aspartate receptor antagonist,is an antiparkinsonian agent. |
In vitro | The primary action of budipine is an indirect dopaminergic effect as shown by facilitation of dopamine (DA) release, inhibition of monoamine oxidase type B (MAO-B) and of DA (re) up-take and stimulation of aromatic L-amino acid decarboxylase (AADC), which in sum might be responsible for enhancing the endogenous dopaminergic activity[1]. |
Molecular Weight | 293.45 |
Formula | C21H27N |
CAS No. | 57982-78-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 2.93 mg/mL (10 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Budipine 57982-78-2 Others monoamine oxidase type B (MAO-B) inhibit CNS disorders Parkinson disease Inhibitor dopaminergic inhibitor